Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Abstract 6360: A tumor agnostic composite gene expression signature identifies three groups of patients treated with immune checkpoint blockade with distinct clinical outcome

Cancer Res (2025) 85 (8_Supplement_1): 6360.

https://doi.org/10.1158/1538-7445.AM2025-6360

Published: 21 April 2025

View articletitled, Abstract 6360: A tumor agnostic composite gene expression signature identifies three groups of patients treated with immune checkpoint blockade with distinct clinical outcome

Journal Articles

Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study

Cancer Res (2024) 84 (9_Supplement): PS08-02.

https://doi.org/10.1158/1538-7445.SABCS23-PS08-02

Published: 02 May 2024

View articletitled, Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study

Journal Articles

Abstract PO3-11-07: Dose-response association between post-diagnosis exercise and clinical outcomes among survivors of breast cancer (BC)

Davide Soldato, Ines Vaz Luis, Julie Havas, Antonio Di Meglio, Neil Iyengar, Barbara Pistilli, Paul Cottu, Florence Lerebours, Charles Coutant, Aurélie Bertaut, Olivier Trédan, Laurence Vanlemmens, Christelle Jouannaud, Ioana Hrab, Sibille Everhard, Anne-Laure Martin, Fabrice André, Lee Jones

Cancer Res (2024) 84 (9_Supplement): PO3-11-07.

https://doi.org/10.1158/1538-7445.SABCS23-PO3-11-07

Published: 02 May 2024

View articletitled, Abstract PO3-11-07: Dose-response association between post-diagnosis exercise and clinical outcomes among survivors of breast cancer (BC)

Journal Articles

Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

Cancer Res (2024) 84 (9_Supplement): GS01-12.

https://doi.org/10.1158/1538-7445.SABCS23-GS01-12

Published: 02 May 2024

View articletitled, Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

Journal Articles

Abstract PO2-03-06: Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)

Cancer Res (2024) 84 (9_Supplement): PO2-03-06.

https://doi.org/10.1158/1538-7445.SABCS23-PO2-03-06

Published: 02 May 2024

View articletitled, Abstract PO2-03-06: Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)

Journal Articles

Abstract PS02-05: Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer

Cancer Res (2024) 84 (9_Supplement): PS02-05.

https://doi.org/10.1158/1538-7445.SABCS23-PS02-05

Published: 02 May 2024

View articletitled, Abstract PS02-05: Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer

Journal Articles

Abstract PO4-14-05: Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC)

Cancer Res (2024) 84 (9_Supplement): PO4-14-05.

https://doi.org/10.1158/1538-7445.SABCS23-PO4-14-05

Published: 02 May 2024

View articletitled, Abstract PO4-14-05: Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC)

Journal Articles

Abstract PO4-17-01: Patient Perception and Decision-Making in HER2+ Early Breast Cancer Management: Insights from the ASKHER2 European Survey

Matteo Lambertini, Christian Jackisch, Olivier Trédan, Maria Vidal, Mário Fontes-Sousa, Antonios Valachis, Rosanna D’Antona, Marcelo Ruz, Eugenia Krone, Miriam Brice, Erwan Berjonneau, Soraia Matos, Olivia Dialla, Laure Guéroult-Accolas

Cancer Res (2024) 84 (9_Supplement): PO4-17-01.

https://doi.org/10.1158/1538-7445.SABCS23-PO4-17-01

Published: 02 May 2024

View articletitled, Abstract PO4-17-01: Patient Perception and Decision-Making in HER2+ Early Breast Cancer Management: Insights from the ASKHER2 European Survey

Journal Articles

Abstract PO4-13-07: Association of clonal hematopoiesis (CH) with clinical outcomes among survivors of breast cancer (BC)

Cancer Res (2024) 84 (9_Supplement): PO4-13-07.

https://doi.org/10.1158/1538-7445.SABCS23-PO4-13-07

Published: 02 May 2024

View articletitled, Abstract PO4-13-07: Association of clonal hematopoiesis (CH) with clinical outcomes among survivors of breast cancer (BC)

Journal Articles

Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

Cancer Res (2024) 84 (9_Supplement): PO2-18-11.

https://doi.org/10.1158/1538-7445.SABCS23-PO2-18-11

Published: 02 May 2024

View articletitled, Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

Journal Articles

Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)

Hope Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal Jhaveri, Monica Motwani, Oh Kyu Yoon, Hao Wang, Wendy Verret, Sara Tolaney

Cancer Res (2023) 83 (5_Supplement): GS1-11.

https://doi.org/10.1158/1538-7445.SABCS22-GS1-11

Published: 01 March 2023

View articletitled, Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)

Journal Articles

Abstract P4-07-24: Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer

Jean-Yves Pierga, Oumar Billa, Sandrine Dabakuyo, Jérôme Lemonnier, Frédérique Berger, Olivier Trédan, William Jacot, Anthony Gonçalves, Marc Debled, Christelle Levy, Christelle Jouannaud, Marie-Ange Mouret-Reynier, Jean-Marc Ferrero, Florence Dalenc, Fatima-Zohra Toumi, Franck Bonnetain, Francois-Clement Bidard, Shufang Renault

Cancer Res (2023) 83 (5_Supplement): P4-07-24.

https://doi.org/10.1158/1538-7445.SABCS22-P4-07-24

Published: 01 March 2023

View articletitled, Abstract P4-07-24: Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer

Journal Articles

Abstract P4-07-54: Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors

Cancer Res (2023) 83 (5_Supplement): P4-07-54.

https://doi.org/10.1158/1538-7445.SABCS22-P4-07-54

Published: 01 March 2023

View articletitled, Abstract P4-07-54: Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors

Journal Articles

Abstract P1-03-04: Visceral fat area as a predictive factor in metastatic HER2 negative breast cancer patients treated by first line chemotherapy with weekly paclitaxel and bevacizumab

Séverine Guiu, Boris Guiu, Marion Chevrier, Oumar Billa, Christelle Levy, Olivier Trédan, Isabelle Desmoulins, Marc Debled, Jean-Marc Ferrero, Christelle Jouannaud, Anthony Gonçalves, Maria Rios, Marie-Ange Mouret-Reynier, Frédérique Berger, Fatima-Zohra TOUMI, Jérôme Lemonnier, Jean-Yves Pierga, Sandrine Dabakuyo, Sophie Gourgou

Cancer Res (2023) 83 (5_Supplement): P1-03-04.

https://doi.org/10.1158/1538-7445.SABCS22-P1-03-04

Published: 01 March 2023

View articletitled, Abstract P1-03-04: Visceral fat area as a predictive factor in metastatic HER2 negative breast cancer patients treated by first line chemotherapy with weekly paclitaxel and bevacizumab

Journal Articles

Abstract P1-13-08: Patterns of adjuvant endocrine therapy, discontinuations, toxicities and quality of life: Development of a model for early discontinuation using the CANTO cohort

Cancer Res (2022) 82 (4_Supplement): P1-13-08.

https://doi.org/10.1158/1538-7445.SABCS21-P1-13-08

Published: 15 February 2022

View articletitled, Abstract P1-13-08: Patterns of adjuvant endocrine therapy, discontinuations, toxicities and quality of life: Development of a model for early discontinuation using the CANTO cohort

Journal Articles

Abstract P4-11-20: Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study

Cancer Res (2022) 82 (4_Supplement): P4-11-20.

https://doi.org/10.1158/1538-7445.SABCS21-P4-11-20

Published: 15 February 2022

View articletitled, Abstract P4-11-20: Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study

Journal Articles

Abstract PS12-05: First efficacy results of a 2-stage Simon’s design randomised phase 2 of darolutamide or capecitabine in patients with triple-negative, androgen receptor positive advanced breast cancer (UCBG06-3)

Hervé Bonnefoi, Florence Lerebours, Olivier Tredan, Florence Dalenc, Christelle Levy, Mahasti Saghatchian, Marie Ange Mouret Reynier, Delphine Mollon, Severine Guiu, Laurence Venat Bouvet, Elisabeth Carola, Geraldine Martineau, Marina Pulido, Gaetan MacGrogan, Anthony Goncalves

Cancer Res (2021) 81 (4_Supplement): PS12-05.

https://doi.org/10.1158/1538-7445.SABCS20-PS12-05

Published: 15 February 2021

View articletitled, Abstract PS12-05: First efficacy results of a 2-stage Simon’s design randomised phase 2 of darolutamide or capecitabine in patients with triple-negative, androgen receptor positive advanced breast cancer (UCBG06-3)

Journal Articles

Abstract OT-38-01: MEDEA: A randomized trial of weight loss to reduce cancer-related fatigue (CRF) among overweight and obese breast cancer (BC) patients

Cancer Res (2021) 81 (4_Supplement): OT-38-01.

https://doi.org/10.1158/1538-7445.SABCS20-OT-38-01

Published: 15 February 2021

View articletitled, Abstract OT-38-01: MEDEA: A randomized trial of weight loss to reduce cancer-related fatigue (CRF) among overweight and obese breast cancer (BC) patients

Journal Articles

Abstract 3390: Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial

Cancer Res (2020) 80 (16_Supplement): 3390.

https://doi.org/10.1158/1538-7445.AM2020-3390

Published: 15 August 2020

View articletitled, Abstract 3390: Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial

Journal Articles

Abstract 4291: VEGFA and VEGFR2 SNPs identify a subgroup of breast cancer patients with favorable outcome under Bevacizumab-based therapy - A message from COMET, a French Unicancer multicentric study

Gerard Milano, Jocelyn Gal, Patrick Brest, Nathalie Ebran, Laurence Llorca, Coraline Dubot, Gilles Romieu, Isabelle Desmoulins, Etienne Brain, Anthony Goncalves, Jean-Marc Ferrero, Paul Cottu, Marc Debled, Olivier Tredan, Emmanuel Chamorey, Marco Carlo Merlano, Jerôme Lemonnier

Cancer Res (2020) 80 (16_Supplement): 4291.

https://doi.org/10.1158/1538-7445.AM2020-4291

Published: 15 August 2020

View articletitled, Abstract 4291: VEGFA and VEGFR2 SNPs identify a subgroup of breast cancer patients with favorable outcome under Bevacizumab-based therapy - A message from COMET, a French Unicancer multicentric study

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 6360: A tumor agnostic composite gene expression signature identifies three groups of patients treated with immune checkpoint blockade with distinct clinical outcome

Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study

Abstract PO3-11-07: Dose-response association between post-diagnosis exercise and clinical outcomes among survivors of breast cancer (BC)

Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

Abstract PO2-03-06: Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)

Abstract PS02-05: Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer

Abstract PO4-14-05: Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC)

Abstract PO4-17-01: Patient Perception and Decision-Making in HER2+ Early Breast Cancer Management: Insights from the ASKHER2 European Survey

Abstract PO4-13-07: Association of clonal hematopoiesis (CH) with clinical outcomes among survivors of breast cancer (BC)

Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)

Abstract P4-07-24: Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer

Abstract P4-07-54: Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors

Abstract P1-03-04: Visceral fat area as a predictive factor in metastatic HER2 negative breast cancer patients treated by first line chemotherapy with weekly paclitaxel and bevacizumab

Abstract P1-13-08: Patterns of adjuvant endocrine therapy, discontinuations, toxicities and quality of life: Development of a model for early discontinuation using the CANTO cohort

Abstract P4-11-20: Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study

Abstract PS12-05: First efficacy results of a 2-stage Simon’s design randomised phase 2 of darolutamide or capecitabine in patients with triple-negative, androgen receptor positive advanced breast cancer (UCBG06-3)

Abstract OT-38-01: MEDEA: A randomized trial of weight loss to reduce cancer-related fatigue (CRF) among overweight and obese breast cancer (BC) patients

Abstract 3390: Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial

Abstract 4291: VEGFA and VEGFR2 SNPs identify a subgroup of breast cancer patients with favorable outcome under Bevacizumab-based therapy - A message from COMET, a French Unicancer multicentric study

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only